Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics cash
Cash and short-term investments held at the end of each period.
Zevra Therapeutics's cash was $221.57M at Jun 30, 2026. For fiscal 2025 it was $191.01M, up 174.9% from the year before. Over ten years it grew 14.0% a year on average. The highest annual figure on record is $191.01M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.01M | +174.9% |
| FY2024 | Dec 31, 2024 | $69.50M | +2.7% |
| FY2023 | Dec 31, 2023 | $67.70M | -17.8% |
| FY2022 | Dec 31, 2022 | $82.37M | -26.7% |
| FY2021 | Dec 31, 2021 | $112.35M | +2566.7% |
| FY2020 | Dec 31, 2020 | $4.21M | +31.0% |
| FY2019 | Dec 31, 2019 | $3.22M | -85.2% |
| FY2018 | Dec 31, 2018 | $21.67M | -48.7% |
| FY2017 | Dec 31, 2017 | $42.23M | -38.7% |
| FY2016 | Dec 31, 2016 | $68.87M | +34.2% |
| FY2015 | Dec 31, 2015 | $51.32M | +400.4% |
| FY2014 | Dec 31, 2014 | $10.26M | +420.8% |
| FY2013 | Dec 31, 2013 | $1.97M | -22.5% |
| FY2012 | Dec 31, 2012 | $2.54M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $221.57M | +9.4% |
| Q1 FY2026 | Mar 31, 2026 | $200.62M | +220.3% |
| Q4 FY2025 | Dec 31, 2025 | $191.01M | +174.9% |
| Q3 FY2025 | Sep 30, 2025 | $199.51M | +123.2% |
| Q2 FY2025 | Jun 30, 2025 | $202.61M | +311.3% |
| Q1 FY2025 | Mar 31, 2025 | $62.63M | +18.8% |
| Q4 FY2024 | Dec 31, 2024 | $69.50M | +2.7% |
| Q3 FY2024 | Sep 30, 2024 | $89.38M | +7.8% |
| Q2 FY2024 | Jun 30, 2024 | $49.26M | -43.3% |
| Q1 FY2024 | Mar 31, 2024 | $52.72M | -29.3% |
| Q4 FY2023 | Dec 31, 2023 | $67.70M | -17.8% |
| Q3 FY2023 | Sep 30, 2023 | $82.94M | +9.3% |
| Q2 FY2023 | Jun 30, 2023 | $86.89M | +7.3% |
| Q1 FY2023 | Mar 31, 2023 | $74.58M | -26.6% |
| Q4 FY2022 | Dec 31, 2022 | $82.37M | -26.7% |
| Q3 FY2022 | Sep 30, 2022 | $75.89M | -42.3% |
| Q2 FY2022 | Jun 30, 2022 | $80.98M | -38.8% |
| Q1 FY2022 | Mar 31, 2022 | $101.58M | +33.8% |
| Q4 FY2021 | Dec 31, 2021 | $112.35M | +2566.7% |
| Q3 FY2021 | Sep 30, 2021 | $131.50M | +2396.7% |
| Q2 FY2021 | Jun 30, 2021 | $132.30M | +1977.2% |
| Q1 FY2021 | Mar 31, 2021 | $75.92M | +3122.3% |
| Q4 FY2020 | Dec 31, 2020 | $4.21M | +31.0% |
| Q3 FY2020 | Sep 30, 2020 | $5.27M | -19.2% |
| Q2 FY2020 | Jun 30, 2020 | $6.37M | -12.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.36M | -82.5% |
| Q4 FY2019 | Dec 31, 2019 | $3.22M | -85.2% |
| Q3 FY2019 | Sep 30, 2019 | $6.52M | -50.0% |
| Q2 FY2019 | Jun 30, 2019 | $7.31M | -74.1% |
| Q1 FY2019 | Mar 31, 2019 | $13.44M | -61.2% |
| Q4 FY2018 | Dec 31, 2018 | $21.67M | -48.7% |
| Q3 FY2018 | Sep 30, 2018 | $13.03M | -71.9% |
| Q2 FY2018 | Jun 30, 2018 | $28.20M | -48.3% |
| Q1 FY2018 | Mar 31, 2018 | $34.62M | -43.4% |
| Q4 FY2017 | Dec 31, 2017 | $42.23M | -38.7% |
| Q3 FY2017 | Sep 30, 2017 | $46.34M | -28.3% |
| Q2 FY2017 | Jun 30, 2017 | $54.59M | – |
| Q1 FY2017 | Mar 31, 2017 | $61.12M | – |
| Q4 FY2016 | Dec 31, 2016 | $68.87M | – |
| Q3 FY2016 | Sep 30, 2016 | $64.63M | – |
See a number that looks wrong?